Kathleen S. Capps - 05 Dec 2025 Form 4 Insider Report for ENANTA PHARMACEUTICALS INC (ENTA)

Reporting relationship: Executive Director of Accounting, Controller (Principal Accounting Officer)
Issuer ticker: ENTA
Reported as of: 05 Dec 2025
Net transaction value: -$4,596
SEC form: 4
Accepted by SEC: 05 Dec 2025, 18:53:20 UTC
Prior SEC filing: 03 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Matthew Kowalsky as attorney-in-fact

Key filing fact

Kathleen S. Capps filed Form 4 for ENANTA PHARMACEUTICALS INC (ENTA) on 05 Dec 2025.

Key facts

This page summarizes Kathleen S. Capps's Form 4 filing for ENANTA PHARMACEUTICALS INC (ENTA).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 05 Dec 2025, 18:53.

Change

Previous filing in this sequence was filed on 03 Dec 2025.
Current net transaction value: -$4,596.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002085127 Primary reporting owner

Capps Kathleen S.

Relationship: Executive Director of Accounting, Controller (Principal Accounting Officer)
Address: C/O ENANTA PHARMACEUTICALS, INC., 4 KINGSBURY AVENUE, WATERTOWN
Signature: /s/ Matthew Kowalsky as attorney-in-fact
Signature date: 05 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ENTA transaction

Common Stock

Sale

Transaction value: $4,596
Shares: -323
Change %: -3.7%
Price: $14.23
Shares after: 8,377
Date: 05 Dec 2025
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents shares sold by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit awards granted on November 23, 2022 and November 22, 2023, as required pursuant to the terms of the award. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the reporting person.

Footnote F2

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $13.89 to $14.46, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

SEC remarks

Executive Director of Accounting, Controller (Principal Accounting Officer)